Advertisement

 

 

Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy.

Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy.
Author Information (click to view)

Lake AC,


Lake AC, (click to view)

Lake AC,

Advertisement

AIDS (London, England) 31(15) 2115-2118 doi 10.1097/QAD.0000000000001599

Abstract

: Hepatitis B virus (HBV) reactivation has been documented in association with multiple immunotherapy regimens . These reactivations can be life-threatening and result in fulminant hepatic failure. There are currently no reports of HBV reactivation on nivolumab treatment. This is a case of a patient with known HIV infection and previous HBV workup that revealed him to be anti-hepatitis B core antibody positive, hepatitis B surface antigen negative, and HBV DNA negative. He experienced a HBV reactivation while on therapy with nivolumab for stage IIIa poorly differentiated carcinoma of the lung, which was a recurrence from a prior surgically resected stage Ia well differentiated adenocarcinoma of the lung. He is a long-term nonprogressor in regards to his HIV and had previously had a negative HBV DNA level and had declined antiretroviral therapy until just prior to starting nivolumab. This case is also of interest as antiprogrammed death-1 receptors are involved in CD4-related HIV control , and the effects of nivolumab in a patient who was an HIV long-term nonprogressor are unknown. There was concern that he would develop increased HIV viremia and CD4-related immune dysfunction without antiretroviral therapy, and thus, he agreed to treatment prior to starting antineoplastic immunotherapy.

Submit a Comment

Your email address will not be published. Required fields are marked *

twelve − 7 =

[ HIDE/SHOW ]